To: LLCF who wrote (945 ) 3/25/1999 7:31:00 PM From: Rocketman Respond to of 3202
PKN can't stand the negative press, so they've hurried out some hype about the 3700:biz.yahoo.com <<<<<<<< PE Biosystems' ABI PRISM 3700 DNA Analyzer Receives Wide Acceptance Thursday March 25, 3:07 pm Eastern Time Company Press Release FOSTER CITY, Calif.--(BW HealthWire)--March 25, 1999--PE Biosystems, a division of Perkin-Elmer (NYSE: PKN - news), has received more than 500 orders for its new ABI PRISM® 3700 DNA Analyzer. Included in this number are 36 additional systems recently ordered by The Sanger Centre in Cambridge, England, one of the instrument's test sites, and the previously announced order for 230 units from Celera Genomics. Four months after shipments of the 3700 began, there are more than 50 instruments operating in 15 test sites around the world. >>>>>>>>>>> Hmmm, so I guess whoever reported that there were 230 units operating at Celera was WRONG!!! Even PKN admits there are only 50 units shipped total worldwide in 4 months. And, they are making a big deal that they have 500 on order, of course 230 of those are to themselves at Celera. HYPE!!! Another interesting thing in this press release shows up below: <<<<<<<< The Sanger Centre's Jane Rogers, Ph.D., Human Sequencing and Mapping project manager, remarked, ''Automation of so many of the steps required by other systems makes the 3700 an attractive option for high-throughput sequencing. Since it takes only 10-15 minutes of operator time to run four plates of samples, many of our resources can be re-deployed to support this throughput increase in other areas of the production process.'' The 3700 represents a 60 percent increase in throughput compared with the existing, commonly used technology - combined with a seven-fold decrease in labor required. >>>>>>>> Notice where in one single paragraph, they go from quoting the Sanger Project Manager, to a sentence about the percentage increase in throughput which is beyond the quotation marks. Is this a statement from the Sanger Manager (contradicting the Science article by the Sanger staff evaluating the unit?), or is this the company tagging on some PR of their own after the quote??? Hmmm, funny how Perkin Elmer doesn't mention the recent research results on their system published in Science. Hype beats published research anytime I guess??? From the Science article on the evaluation of the 3700 since December by the Sanger Centre Research and Development department researchers James Mullikin and Amanda McMurray: <<<<<< Our results show that read length obtained from the ABI 3700 sequencer is currently shorter than that obtained from the same type of samples sequenced on slab gel machines. This, coupled with the fact that the ABI 377XL-96 (at roughly half the price of the ABI 3700) has a throughput of three plates per day as opposed to the current maximum throughput of six plates per day for the ABI 3700, means that there is no immediate gain in throughput in terms of capital investment. Capillary sequencers already established in the marketplace, however, have attained read lengths comparable to those from slab gel machines; the Molecular Dynamics MegaBACE 1000 can read 600 to 700 bases and Perkin-Elmer's single capillary sequencer, the ABI 310, produces read lengths of around 600 bp. >>>>>>>>>